Lisa Lynn Decker
CIK 1783056 · CHIEF BUSINESS OFFICER · last filed 2025-07-25
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
IGMS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
500 SAGINAW DRIVE
REDWOOD CITY, CA 94063
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IGM Biosciences, Inc. (IGMS) Delisted | CHIEF BUSINESS OFFICER | 68,169 | $1.27 | $86.6K | -$237.7K | 23 | 2025-07-25 |
| CHIMERIX INC (CMRX) Delisted | Director | — | $8.54 | — | $0 | 3 | 2025-04-21 |
| Atreca, Inc. (BCEL) Delisted | Chief Business Officer | — | $0.15 | — | $0 | 2 | 2021-01-29 |
Recent Filings · Page 3 of 3
30 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-12-20 | IGM Biosciences, Inc. (IGMS) Delisted | Sell (S) | −2,484 | -$47.2K | EDGAR |
| 2022-11-28 | IGM Biosciences, Inc. (IGMS) Delisted | Sell (S) | −1,258 | -$27.1K | EDGAR |
| 2022-05-26 | IGM Biosciences, Inc. (IGMS) Delisted | Sell (S) | −1,362 | -$23.3K | EDGAR |
| 2022-05-17 | IGM Biosciences, Inc. (IGMS) Delisted | Grant (A) | +413 | $5.1K | EDGAR |
| 2022-03-17 | IGM Biosciences, Inc. (IGMS) Delisted | Grant (A) | +4,617 | $0 | EDGAR |
| 2022-03-15 | IGM Biosciences, Inc. (IGMS) Delisted | Grant (A) | +7,500 | $0 | EDGAR |
| 2021-11-19 | IGM Biosciences, Inc. (IGMS) Delisted | Grant (A) | +10,000 | $0 | EDGAR |
| 2021-11-17 | IGM Biosciences, Inc. (IGMS) Delisted | Grant (A) | +367 | $18.7K | EDGAR |
| 2021-01-29 | Atreca, Inc. (BCEL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-02-28 | Atreca, Inc. (BCEL) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.